We’ve heard a lot lately about superbugs – bacteria that are resistant to current antibiotics. But as the threat of superbugs continues to rise, the number of new treatments available has flatlined. This…
Academic rigor, journalistic flair
Articles on Drug development
Displaying 81 - 100 of 107 articles
An ambitious project has been launched that will involve sequencing genomes of 100,000 individuals to improve our understanding of a range of diseases and – hopefully – eventually find new treatments for…
The rise of bacteria that are resistant to antibiotics is a growing worry and threatens to put healthcare back to the early 20th century. Such resistance to drugs was inevitable, because bacteria evolve…
Disease can affect any person, rich or poor. While your bank balance can’t really protect you from getting sick, it could potentially buy you – and many other patients – access to a better treatment for…
Development of new drugs for treatment of disease is an expensive, time-consuming and labour-intensive effort for both pharmaceutical companies and academics. For the past 15 years, “cost per approval…
Foundation essay: This article is part of a series marking the launch of The Conversation in the US. Our foundation essays are longer than our usual comment and analysis articles and take a wider look…
It can take 12 years and more than £1 billion to create a new medicine. But when we swallow a capsule, squeeze those eye drops or administer an injection, we rarely stop to think about the work that has…
The extent of the current Ebola virus outbreak in West Africa has belatedly focused the attention of non-governmental organisations, local and Western governments, and international media. What we haven’t…
Ebola virus disease typically only occurs in rural and remote areas among resource-poor populations. Until the large, recent outbreak in West Africa, cases of the illness were a rarity. So the fact that…
Researchers in the UK have created an atlas of genetic associations with metabolic molecules, providing new insights into…
The National Institute for Health and Care Excellence (NICE) has published new draft proposals laying out major changes to the way it assesses whether new medicines offer value for money for the NHS. These…
Developing new drugs is hard and expensive. The lengthy process from initial discovery to the market is some times compared to the difficulty of putting a person on the moon. Despite accusations that the…
New research has revealed that venom can be stored for up to 80 years without losing any of its biological properties. Researchers…
Daily jabs of insulin are a painful reality for many with diabetes. That may change if researchers who have successfully tested oral insulin in rats are able to replicate those results in humans. Nearly…
It has been described as a historical “turning point” in Alzheimer’s treatment - the first time a chemical has been found that can halt the death of brain tissue in a neurodegenerative disease, and could…
While scientists develop new drugs to treat a multitude of conditions, nanotechnology is pushing the boundaries of how we deliver them to patients - targeting delivery to cancer cells and giving a drug…
Many therapeutic drugs and toxins affect us without us knowing exactly how. We know, for example, that Epilim, or sodium valproate, one of the most highly prescribed medicines for epilepsy can prevent…
A British scientist convicted of scientific fraud last month for falsifying research data has been sentenced to three months jail. Steven Eaton is the first person to serve time under the UK’s Good Laboratory…
Bacteria are one of the most successful colonisers of the planet. They can be found in almost all environments we know – from the deepest oceans to acid lakes, and inside and on our bodies. And the history…
Most experts considering the subject agree that the antibiotic development pipeline is not sufficient by a long shot. The days when there was always a new antibiotic just around the corner to treat the…
Top contributors
-
Prof. Institute for Molecular Bioscience, The University of Queensland
-
Assistant Professor of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus
-
Associate Professor of History, University of Wollongong
-
Biostatistician, The University of Melbourne
-
Professor of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
-
Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Professor of Neuroscience, Lancaster University
-
Professor, UNSW Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Biostatistics, Murdoch Children's Research Institute
-
Director of Natural Product Discovery Core; Assistant Professor of Medicinal Chemistry, University of Michigan
-
Molecular and Clinical Pharmacology, University of Liverpool
-
Researcher, L’Université d’Ottawa/University of Ottawa
-
Executive General Manager Commercialisation and Research Contracts, Baker Heart and Diabetes Institute
